Novo Nordisk is eyeing the hair-loss market as the maker of Ozempic seeks to expand its direct-to-consumer pharmaceutical business.
The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scientific expertise or the skills it's recently built in selling prescription drugs directly to consumers.
